Reading Your Biology - The New Language of Longevity
DR YAN LABS · LONGEVITY SCIENCE
Aging is becoming measurable. That single fact is quietly rewriting what an ingredient has to prove before it can call itself longevity science.
READING YOUR BIOLOGY · SOCIAL SERIES EXPANDED
Something quiet but fundamental is happening in longevity science, and most of the beauty and supplement industry has not caught up with it yet.
Aging is becoming measurable. Not you look tired today measurable. Not your skin seems dehydrated measurable. Molecularly, epigenetically, quantifiably measurable, with a number attached and a confidence interval around it.
For a century, aging was something we described. We are now in the first period in which it can be read. And when a biological process becomes readable, everything built on top of it has to change: the questions consumers ask, the claims a formulator can defend, and the standard a raw material supplier is held to.
This article closes our series on that shift. It covers three things: how aging became measurable, the twelve-process framework that modern longevity science actually runs on, and the three criteria we believe separate a longevity ingredient from a marketing narrative. At the end, we apply those criteria to our own molecule - including where the evidence stops.
THE CLOCK INSIDE YOUR CELLS
In 2013, Steve Horvath described something that should not have worked as well as it did. By reading the methylation state of a few hundred sites on the genome, small chemical marks that sit on DNA and change how genes are expressed. He could estimate a person's age across almost any tissue in the body, more accurately than most conventional clinical markers.
That was one of the first multi-tissue epigenetic clocks. The generation that followed was more interesting still. GrimAge, published by Lu and colleagues in 2019, was not trained on chronological age at all; it was trained on mortality-associated plasma proteins and smoking history, and it predicts lifespan and healthspan across multiple independent cohorts. DunedinPACE, built on a birth cohort followed for decades, does something different again: rather than estimating how old you are, it estimates how fast you are currently aging: how many biological years you accrue per calendar year.
Read these clocks the way the people who build them do, and they get more interesting, not less. A clock is a readout, not a dial - it tells you where the biology has arrived, not which lever moved it there. Two clocks can disagree on the same blood sample and both be informative, because they were trained to answer different questions. And a single result is a photograph of something that only means anything as film: the direction of travel is the finding, never the frame.
That is precisely why this matters commercially. Biological age testing has left the research group for direct-to-consumer diagnostics. A growing number of people now hold a number describing their own biology, and a year later, a second one to set beside it. For the first time in the history of this industry, a customer can put a product between two measurements and ask what happened in between.
A consumer who knows their biological age stops asking what a product looks like it does, and starts asking what it does.
That is a different question, and for most cosmetic and supplement ingredients on the market, the honest answer is: we don't know. Not because the industry is dishonest, but because "reduces the appearance of fine lines" and "acts on a mechanism of aging" have never had to be the same sentence before. Now they do.
TWELVE PROCESSES, NOT ONE
If aging is measurable, the next question is what exactly is being measured. Modern longevity biology has a working answer, and it is not a metaphor about free radicals.
In 2023, Carlos López-Otín, María Blasco, Linda Partridge, Manuel Serrano and Guido Kroemer published an updated framework in Cell: twelve hallmarks of aging, expanded from the nine they proposed in 2013. It is now the most cited conceptual structure in the field. Each hallmark must satisfy three conditions: it appears during normal aging, aggravating it experimentally accelerates aging, and attenuating it experimentally delays, prevents or reverses aging.
They divide into three tiers: the damage, the response to the damage, and the consequences that follow.
PRIMARY HALLMARKS - THE DAMAGE ITSELF
Genomic instability - DNA damage accumulates faster than repair systems can clear it, from replication errors, radiation and reactive metabolites.
Telomere attrition - The protective caps on chromosome ends shorten with each division until cells stop dividing altogether.
Epigenetic alterations - Methylation and histone patterns drift, and cells gradually lose the instructions that define what they are. This is the layer the clocks read.
Loss of proteostasis - The machinery that folds, repairs and disposes of proteins loses accuracy, and misfolded proteins accumulate.
ANTAGONISTIC HALLMARKS - RESPONSES THAT TURN HARMFUL
Disabled macroautophagy - The cell's recycling system slows, leaving damaged organelles and aggregates in place.
Deregulated nutrient sensing - The network that reads nutrient availability: insulin/IGF-1, mTOR, AMPK, sirtuins - loses its calibration.
Mitochondrial dysfunction - Energy production falls while reactive oxygen species rise, and the two reinforce each other.
Cellular senescence - Cells stop dividing but refuse to die, secreting an inflammatory cocktail known as the SASP into the tissue around them.
INTEGRATIVE HALLMARKS - THE CONSEQUENCES
Stem cell exhaustion - The regenerative reserve that replaces lost cells is depleted, and repair slows.
Altered intercellular communication - Signalling between cells degrades - including, in skin, the breakdown of extracellular matrix homeostasis by matrix metalloproteinases.
Chronic inflammation - Low-grade, persistent, sterile inflammation - inflammaging - driven largely by NF-κB signalling.
Dysbiosis - The microbial communities we depend on shift in composition and function.
Now the uncomfortable question. Which of these does a typical skincare or supplement product actually address?
Most commonly two: oxidative stress, which sits adjacent to mitochondrial dysfunction, and inflammation. Occasionally a third: cellular senescence - when the ingredient has been chosen with real intent. That leaves nine or ten hallmarks that most formulations on the market do not touch at all.
There are twelve hallmarks of aging. Most products address two. That is not an accusation - it is a map of where the frontier is.
THREE CRITERIA FOR A LONGEVITY INGREDIENT
If aging is measurable and biology gives us twelve processes to work with, then the question for a formulator becomes precise rather than promotional. What actually qualifies an ingredient as longevity-oriented? We use three tests, and an ingredient has to pass all three.
One - Mechanism
The ingredient must act on an identified hallmark of aging, not simply produce a cosmetic effect. "Reduces the appearance of wrinkles" is an outcome; it describes what a person sees. "Inhibits MMP-9 and elastase activity in human dermal fibroblasts" is a mechanism; it describes what the molecule does. Outcomes without mechanisms are the reason so much of this category is unfalsifiable - you cannot disprove an appearance.
Two - Evidence
The mechanism must be documented in peer-reviewed literature for that molecule, not extrapolated from a structurally related compound, a plant extract containing it, or a well-told story. Pre-clinical evidence is entirely acceptable when it is labelled as pre-clinical: a finding in a senescence-accelerated mouse model is real data and should be named as such. What is not acceptable is the quiet grammatical slide from "in mice" to "clinically proven".
Three - Delivery
This is the criterion the industry skips most often. A molecule must reach its target in a stable, bioavailable form. Many of the most interesting longevity bioactives are poorly soluble, unstable in formulation, or unable to cross the barrier they are asked to cross. An ingredient that degrades in the jar or never reaches the dermis does nothing biologically, no matter how elegant its mechanism data looks on a slide. Mechanism without delivery is a hypothesis, not a product.
Mechanism. Evidence. Delivery. Most longevity ingredients meet the first. Some meet two. Very few meet all three.
THE AUDIT WE RAN ON OUR OWN MOLECULE
A framework you only point at competitors is a sales tool. So we turned it on ourselves, and we are publishing the result.
Xanthohumol is the prenylated chalcone that hop cones produce in quantities no other plant in the human diet comes close to, and the molecule our entire business is built on. It is also one of the few compounds in this category to have been carried all the way into human intervention trials, rather than stopping at the cell line. Measured against the twelve hallmarks, here is where it lands, hallmark by hallmark, citation by citation.
Hallmark 10 · Altered intercellular communication
The strongest card in the deck, and it was played in human dermal fibroblasts. The exact cells that build and maintain the dermis. Philips and colleagues (2010) recorded xanthohumol doing two opposite things at once: shutting down the enzymes that dismantle the matrix - MMP-9 and elastase inhibited at the lowest concentrations tested, MMP-1 and MMP-2 at higher ones, while simultaneously driving the synthesis of what the matrix is made of: collagen types I, III and V, elastin, and fibrillins 1 and 2.
Most actives manage one side of that equation. Xanthohumol closed the drain and opened the tap in the same cells, in the same experiment. The authors' own words: dual protective effects on the extracellular matrix.
Hallmark 11 · Chronic inflammation
Inflammaging is the hallmark that feeds the others. It accelerates matrix breakdown, barrier failure and senescence downstream of itself. In SAMP8 mice, an animal line bred specifically to age fast, Fernández-García and colleagues (2018) recorded xanthohumol suppressing the central inflammatory axis: NF-κB2, TNF-α and IL-1β down; the antioxidant enzymes HO-1 and eNOS up; the apoptotic markers BAD and BAX reduced. At 1 and 5 mg/kg. Over thirty days. Kołodziejczak and colleagues (2024) confirm the same NF-κB and cytokine picture in skin.
Hallmark 6 · Deregulated nutrient sensing
The same study found xanthohumol modulating Sirtuin 1 - the NAD⁺-dependent enzyme sitting at the centre of the nutrient-sensing network alongside mTOR and AMPK, and one of the most intensively studied longevity proteins in biology. Not a peripheral finding. A molecule that reaches into that network is operating on the machinery the entire field is built around.
Hallmark 5 · Disabled macroautophagy
Autophagy is the cell's recycling system - the process that clears damaged organelles and protein aggregates before they accumulate, and it slows with age. In 2025, Xia and colleagues published in Phytomedicine the most mechanistically complete piece of xanthohumol research to date, and its central finding is unusually precise: mTOR is a direct molecular target of xanthohumol.
Not inferred from a downstream readout. Identified by five orthogonal binding methods: DARTS, molecular docking, molecular dynamics, cellular thermal shift assay and microscale thermophoresis, and then confirmed in living animals against both an mTOR agonist and rapamycin itself. Across twelve weeks in a D-galactose model of accelerated aging, xanthohumol restored autophagic flux, driving autophagosomes through to autolysosomes and raising beclin-1, and the aged animals improved on both bone quality and cognitive performance.
Then the experiment that matters. When the researchers blocked autophagy with 3-methyladenine, or by silencing beclin-1 - xanthohumol's protective effect disappeared entirely. The mechanism is not merely correlated with the benefit. It carries it.
mTOR is the switch that caloric restriction and rapamycin act through: the single most studied intervention point in the whole of longevity biology. Very few natural compounds have ever been shown to bind it directly.
Hallmarks 4 and 7 · Proteostasis and mitochondrial function
Xanthohumol is a well-replicated activator of Nrf2, and Nrf2 is not an antioxidant. It is the master switch that turns on the cell's own antioxidant and detoxification program, an entire coordinated defensive response written into the genome. Reaching the switch is a categorically different proposition from adding one more scavenger molecule to a formula, and it is the mechanism through which xanthohumol reduces the oxidative pressure that degrades both mitochondrial function and protein quality control.
The same 2025 study carries one more signal worth naming. In the aged osteoblasts, xanthohumol reduced markers of cellular senescence - hallmark 8 - alongside reduced apoptosis and restored differentiation. That is bone, not skin, and one study is one study. But it is the first direct reading on that hallmark, and it points at the experiment nobody has yet run.
Four hallmarks with direct documented activity, from four separate research groups on three continents. Two more reached through Nrf2. A first signal on a seventh. The remainder - telomere attrition, epigenetic alterations, stem cell exhaustion, dysbiosis and genomic instability, is open territory, and it is moving fast: the mTOR finding above did not exist two years ago.
We print that inventory deliberately, because it is the one our competitors will not print. Every ingredient in this category is now marketed against twelve hallmarks. Ask which hallmark, in which model, with which citation, and the conversation usually ends there.
Anyone can claim twelve hallmarks. We publish the inventory - four documented, two through Nrf2, one direct molecular target, and the frontier we are still working on. That is what a supplier does when it expects to be checked.
It is also, bluntly, a commercial strategy. Our customers are formulators and R&D directors. They read the primary literature, they check the model, and they remember which supplier's dossier survived the check. In a category where almost everything is asserted, the material that can be verified is the material that gets specified.
And then there is the third criterion - the one that quietly disqualifies most of the field. Xanthohumol is poorly water-soluble with real bioavailability constraints. We know this, which is exactly why we build it in liposomal form. Mechanism and evidence are worth nothing if the molecule never arrives at the cell that needs it.
THE VOCABULARY IS SHIFTING
Return to where this started. When aging was something we described, product language could stay in the register of appearance, and it did. When aging becomes something we measure, that language starts to look thin - not to regulators first, but to customers, who now have a number of their own and a reason to ask what moves it.
The next generation of longevity formulations will not be judged on how many antioxidants they contain. They will be judged on which hallmarks they measurably influence, on what tissue and in what model that was shown, and on whether the molecule arrives intact at the place the mechanism requires.
That is a higher bar. We think it is the right one, and we would rather be measured against it early than caught by it late.
Longevity that arrives.
SOURCES
- Horvath S. (2013). "DNA methylation age of human tissues and cell types." Genome Biology 14:R115. pubmed.ncbi.nlm.nih.gov/24138928
- Lu A.T. et al. (2019). "DNA methylation GrimAge strongly predicts lifespan and healthspan." Aging (Albany NY) 11(2):303–327. pubmed.ncbi.nlm.nih.gov/30669119
- Belsky D.W. et al. (2022). "DunedinPACE, a DNA methylation biomarker of the pace of aging." eLife 11:e73420. pubmed.ncbi.nlm.nih.gov/35029144
- López-Otín C., Blasco M.A., Partridge L., Serrano M., Kroemer G. (2023). "Hallmarks of aging: An expanding universe." Cell 186(2):243–278. DOI: 10.1016/j.cell.2022.11.001. pubmed.ncbi.nlm.nih.gov/36599349
- López-Otín C. et al. (2013). "The hallmarks of aging." Cell 153(6):1194–1217. (Original nine-hallmark framework.)
- Tartiere A.G., Freije J.M.P., López-Otín C. (2024). "The hallmarks of aging as a conceptual framework for health and longevity research." Frontiers in Aging 5:1334261. DOI: 10.3389/fragi.2024.1334261
- Philips N., Samuel M., Arena R., Chen Y.J., Conte J., Natrajan P., Haas G., Gonzalez S. (2010). "Direct inhibition of elastase and matrixmetalloproteinases and stimulation of biosynthesis of fibrillar collagens, elastin, and fibrillins by xanthohumol." Journal of Cosmetic Science 61(2):125–132. pubmed.ncbi.nlm.nih.gov/20447364
- Fernández-García B. et al. (2018). "Xanthohumol exerts protective effects in liver alterations associated with aging." European Journal of Nutrition. DOI: 10.1007/s00394-018-1657-6
- Kołodziejczak A. et al. (2024). "A Novel Look at Mechanisms and Applications of Xanthohumol (XN) in Dermatology and Cosmetology." International Journal of Molecular Sciences 25(22):11938. DOI: 10.3390/ijms252211938 .
- Oledzka E. (2024). "Xanthohumol—A Miracle Molecule with Biological Activities: A Review of Biodegradable Polymeric Carriers and Naturally Derived Compounds for Its Delivery." International Journal of Molecular Sciences 25(6):3398. DOI: 10.3390/ijms25063398
- Piekara J., Piasecka-Kwiatkowska D. (2024). "Antioxidant Potential of Xanthohumol in Disease Prevention: Evidence from Human and Animal Studies." Antioxidants 13(12):1559. DOI: 10.3390/antiox13121559
- Xia T.-S., Xu S.-Y., Jiang Y.-P., Li K., Zhu R.-Q., Han T., Xin H.-L. (2025). "Therapeutic potential of xanthohumol in senile osteoporosis: mTOR-driven regulation of AKT/mTOR/p70S6K autophagy axis in D-galactose models." Phytomedicine 148:157346. DOI: 10.1016/j.phymed.2025.157346.
- Ferk F. et al. (2016). "Impact of xanthohumol (a prenylated flavonoid from hops) on DNA stability and other health-related biochemical parameters: Results of human intervention trials." Molecular Nutrition & Food Research. DOI: 10.1002/mnfr.201500355
Each finding above is reported with the model it was established in human dermal fibroblasts, SAMP8, and the cited reviews, so that any reader can go to the source and check it. This article is written for formulators and industry professionals; it describes mechanisms documented in the scientific literature and is not medical advice.